Is there an FDA-approved GLP-1 patch?

No. As of May 2026, no FDA-approved transdermal patch contains semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, or orforglipron. All seven FDA-approved GLP-1 receptor agonists are delivered either by subcutaneous injection (Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza, Trulicity, Byetta, Bydureon) or by oral tablet (Rybelsus for type 2 diabetes; Foundayo for chronic weight management, approved April 1, 2026). Products marketed as 'GLP-1 patches' contain no GLP-1 receptor agonist.

Why can't GLP-1 drugs be delivered through a skin patch?

Two reasons. First, molecular weight: the canonical '500 Dalton rule' (Bos and Meinardi, Exp Dermatol 2000, PMID 10839713) holds that only molecules under approximately 500 Daltons reliably cross the skin's stratum corneum barrier. Semaglutide is 4,113 Da, tirzepatide is 4,813 Da, and liraglutide is 3,751 Da — roughly 7-10 times too large. Second, peptide degradation: human skin contains proteases that cleave peptide bonds. Even if a small fraction of a peptide drug somehow crossed the barrier, it would be enzymatically broken down before reaching systemic circulation. This is why every FDA-approved injectable GLP-1 is administered subcutaneously, not topically.

What is actually in a 'GLP-1 patch' product sold online?

It varies by seller, but the consistent finding is: not GLP-1. Common formulations include (a) acupressure or 'ear seed' style stickers with no active pharmaceutical ingredient at all; (b) herbal 'belly fat' patches containing caffeine, green tea extract, garcinia cambogia, l-carnitine, or capsaicin — none of which are GLP-1 receptor agonists; (c) compounded peptide creams from grey-market compounders, which face the same molecular-weight problem as the brand drugs; and (d) MLM 'lifestyle patches' described in unfalsifiable terms (frequencies, body wisdom, energy fields). None deliver semaglutide or tirzepatide systemically.

Has the FDA taken action against weight-loss patch sellers?

Yes — repeatedly, by both the FDA and the FTC. The FTC's case against Jason Cardiff and Redwood Scientific Technologies (case 172-3117-X190001, 2018) targeted deceptive weight-loss and smoking-cessation strip products. The FDA's Tainted Weight Loss Products database and Warning Letters database catalogue ongoing enforcement against products making unsubstantiated weight-loss claims. The FDA's consumer guidance on fraudulent weight-loss products is published at fda.gov/consumers/consumer-updates/avoiding-fraudulent-weight-loss-products.

What is the legitimate alternative if I don't want injections?

Two FDA-approved oral GLP-1 receptor agonists exist. Rybelsus (oral semaglutide, Novo Nordisk) is FDA-approved for type 2 diabetes and is used off-label for weight loss; it requires a strict fasting protocol because absorption depends on the SNAC excipient. Foundayo (oral orforglipron, Eli Lilly) was FDA-approved April 1, 2026 for chronic weight management; the ATTAIN-1 trial showed mean weight loss of -11.1% at 17.2 mg over 72 weeks (Wharton et al., NEJM 2025, PMID 40960239). Orforglipron is a non-peptide small-molecule (~487 Da), so it survives oral digestion without an absorption enhancer. Both require a prescription from a licensed prescriber.

Are there any preclinical microneedle patches for GLP-1 drugs in development?

Yes — but they are preclinical, not FDA-approved, and not for sale. Researchers have published proof-of-concept microneedle array designs that load semaglutide into dissolvable polymer needles (Woo et al., Int J Nanomedicine 2025, PMID 41030572; Singh et al., Adv Ther 2024, PMID 39429250). These are animal or in-vitro studies. No transdermal or microneedle GLP-1 product has reached Phase 2 or Phase 3 human trials or filed an FDA New Drug Application as of May 2026. Microneedle technology bypasses the stratum corneum mechanically, which is a fundamentally different delivery route from a passive transdermal patch.

Can compounded semaglutide cream cross the skin?

Not in pharmacologically meaningful amounts. Compounding pharmacies can formulate almost any active ingredient into almost any vehicle on paper, but molecular weight is a physical barrier compounding cannot overcome. Semaglutide's 4,113 Da peptide structure cannot meaningfully cross intact skin, with or without permeation enhancers. A compounded transdermal semaglutide product would, at best, deliver an unknown sub-therapeutic dose; at worst, deliver zero active drug. No reputable 503A or 503B compounding pharmacy with an active quality program markets a transdermal GLP-1 product.

Do auricular acupressure 'ear patches' help with weight loss?

The evidence is weak. A 2024 systematic review of auricular stimulation for weight and obesity-related parameters (Hua et al., Front Neurosci 2024, PMID 39165337) found modest effects across mostly low-quality trials. Even if real, that mechanism is NOT GLP-1 receptor agonism. Calling an acupressure sticker a 'GLP-1 patch' is a marketing claim with no pharmacological basis. The auricular pressure point literature is its own evidence base, distinct from anything involving GLP-1.

Are GLP-1 Patches Real? FDA Approval Status & Honest Evidence Review

0FDA-approved GLP-1 patches (May 2026)

This evidence review is part of Weight Loss Rankings’ living editorial database — 300+ research articles and 190+ clinically-reviewed GLP-1 telehealth providers, sourced only from FDA prescribing information on DailyMed and peer-reviewed PubMed literature.

Search “GLP-1 patches” and you will find dozens of products promising injection-free semaglutide, tirzepatide, or “natural Ozempic” absorbed through your skin. None of them work. As of May 2026, no FDA-approved transdermal GLP-1 receptor agonist exists, and there is a clear mechanical reason: GLP-1 peptides are 7 to 10 times too large to cross intact skin. This article walks through the regulatory status, the molecular-biology argument, what these products actually contain, the FDA and FTC enforcement record, and the two FDA-approved oral alternatives for people who do not want injections.

The honest answer

No FDA-approved GLP-1 patch exists. Every product marketed as a “GLP-1 patch” is one of four things: an acupressure sticker with no active drug, a herbal “belly fat” patch containing caffeine or green tea extract, a compounded peptide cream that cannot meaningfully cross skin, or an MLM “lifestyle patch” with no pharmacological mechanism. The two FDA-approved needle-free options are oral tablets, not patches: Rybelsus (oral semaglutide; T2D-only) and Foundayo (oral orforglipron; FDA-approved April 2026 for chronic weight management).

There is no FDA-approved GLP-1 patch

Seven GLP-1 receptor agonist drugs are FDA-approved in the United States. Every one is delivered either by subcutaneous injection or by an oral tablet — not by transdermal patch:

Active ingredient	Brand	Route	FDA-approved indication
Semaglutide	Wegovy, Ozempic	Subcutaneous injection	Chronic weight management (Wegovy); T2D (Ozempic)
Semaglutide	Rybelsus	Oral tablet	T2D only (off-label for weight)
Tirzepatide	Zepbound, Mounjaro	Subcutaneous injection	Chronic weight management (Zepbound); T2D (Mounjaro)
Liraglutide	Saxenda, Victoza	Subcutaneous injection	Chronic weight management (Saxenda); T2D (Victoza)
Dulaglutide	Trulicity	Subcutaneous injection	T2D
Exenatide	Byetta, Bydureon	Subcutaneous injection	T2D
Orforglipron	Foundayo	Oral tablet	Chronic weight management (approved April 2026)

Searches of Drugs@FDA, the FDA Orange Book, and the FDA New Drug Application pipeline for any “transdermal” or “patch” dosage form containing a GLP-1 receptor agonist return zero results as of May 2026. No NDA filing for a transdermal GLP-1 has been publicly announced by Novo Nordisk, Eli Lilly, or any other developer.

Why GLP-1 patches don’t work (the 500 Dalton rule)

The reason no manufacturer has produced a transdermal GLP-1 product is not a regulatory accident. It is a physical-chemistry constraint.

Bos and Meinardi’s widely-cited 2000 review in Experimental Dermatology established what dermatology now calls the “500 Dalton rule”: drug molecules with a molecular weight under approximately 500 Daltons can pass through the stratum corneum — the skin’s outermost barrier layer — in pharmacologically meaningful quantities. Molecules over 500 Da generally cannot.^[1]

The molecular weights of the FDA-approved GLP-1 peptides are not close to that limit:

Semaglutide: 4,113.58 Da — a 31-amino-acid synthetic GLP-1 analogue with a C18 fatty-diacid side chain for albumin binding^[2].
Tirzepatide: 4,813.53 Da — a 39-amino-acid dual GIP/GLP-1 receptor agonist peptide^[3].
Liraglutide: 3,751.20 Da — a 34-amino-acid acylated GLP-1 analogue.

These molecules are 7 to 10 times larger than the upper limit for passive skin penetration. There is no published formulation chemistry that overcomes this gap for a passive transdermal patch.

Magnitude comparison

Molecular weights of FDA-approved GLP-1 receptor agonists versus the 500 Dalton rule for transdermal delivery. Every injectable GLP-1 peptide is multiples larger than the skin permeation limit; only orforglipron (Foundayo), a non-peptide small molecule, falls under the threshold but it is formulated as an oral tablet, not a patch.^[1]^[2]^[3]^[9]

Tirzepatide (Zepbound, Mounjaro)4814 Da
39-amino-acid peptide — 9.6x over the 500 Da limit
Semaglutide (Wegovy, Ozempic, Rybelsus)4114 Da
31-amino-acid peptide — 8.2x over the limit
Liraglutide (Saxenda, Victoza)3751 Da
34-amino-acid peptide — 7.5x over the limit
500 Dalton rule (transdermal upper limit)500 Da
Bos & Meinardi, Exp Dermatol 2000 — skin penetration ceiling
Orforglipron (Foundayo)487 Da
Non-peptide small molecule — under the limit but formulated as oral tablet

Even hypothetically — if a peptide of this size somehow crossed the stratum corneum — it would face a second obstacle: human skin contains proteases that cleave peptide bonds. Drucker’s 2020 review of oral and non-injectable peptide delivery in Nature Reviews Drug Discovery catalogues the enzymatic and permeability barriers that confine almost all therapeutic peptides to the injectable route.^[4]

Why Rybelsus (oral semaglutide) works but a patch wouldn’t

Rybelsus is the one exception that proves the rule. Novo Nordisk formulated oral semaglutide using an absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), which creates a brief window of stomach-membrane permeability under strict fasting conditions. The result is an absolute oral bioavailability of approximately 1% — enough to be clinically useful, but only because the stomach can be temporarily made more permeable. Skin has no equivalent “trick.”^[5]

Microneedle research exists, but it is preclinical and not for sale

Researchers have published proof-of-concept microneedle array designs that load semaglutide into dissolvable polymer needles, mechanically bypassing the stratum corneum. Woo et al. (2025) and Singh et al. (2024) demonstrated such patches in rodent obesity models.^[10]^[11] These are preclinical formulation studies. None has reached human Phase 1, 2, or 3 trials. None has filed an FDA New Drug Application. A microneedle patch is also a different category from a passive transdermal patch — the needles physically pierce the skin, which is closer to a self-administered micro-injection than to a nicotine patch. Nothing of this kind is commercially available as of May 2026.

What “GLP-1 patches” actually contain

Products marketed online as “GLP-1 patches”, “Ozempic patches”, “semaglutide patches”, or “natural Ozempic patches” fall into four recurring categories. None of them deliver a GLP-1 receptor agonist across the skin.

1. Acupressure or “ear seed” stickers

These are adhesive stickers placed on the ear, abdomen, or other body sites. They contain no active pharmaceutical ingredient. The claimed mechanism is acupressure stimulation. A 2024 systematic review of auricular stimulation for weight loss found modest effects across predominantly low-quality trials — and even those modest effects are unrelated to the GLP-1 receptor.^[12] Calling an acupressure sticker a “GLP-1 patch” is a marketing claim, not a pharmacological description.

2. Herbal “belly fat” patches

These patches contain plant-derived compounds such as caffeine, green tea extract (EGCG), garcinia cambogia, l-carnitine, capsaicin, or guarana. Some of those compounds are small enough (under 500 Da) to cross skin in theory, but none has Phase 3 randomized-controlled-trial evidence for clinically meaningful weight loss in patch form. None is a GLP-1 receptor agonist. The marketing label “GLP-1” is affixed for search-and-conversion reasons, not because the patch engages the GLP-1 pathway.

3. Compounded peptide creams

A small grey-market segment compounds semaglutide or tirzepatide into transdermal vehicles — creams, gels, or lipid emulsions. Even with permeation enhancers, the molecular-weight problem remains: compounding does not change the size of the molecule. A compounded transdermal semaglutide product, at best, would deliver an unknown sub-therapeutic dose; at worst, would deliver zero active drug. No reputable 503A or 503B compounding pharmacy with a publicly published quality program markets a transdermal GLP-1 preparation. If a clinic offers one, the appropriate question is which licensed pharmacy is producing it and what bioavailability evidence supports the route.

4. MLM “lifestyle” patches

Multi-level-marketing companies sell stick-on patches with claimed metabolic, appetite, or weight-loss effects. The mechanism is usually described in unfalsifiable terms — energy fields, frequencies, body wisdom, biofield resonance. These descriptions are not pharmacological. The patches contain no GLP-1 receptor agonist and no active drug that has passed FDA review for weight management.

FDA and FTC enforcement against weight-loss patches

Federal enforcement against fraudulent weight-loss patch and strip products is not new. Both the Federal Trade Commission (responsible for false-advertising actions) and the Food and Drug Administration (responsible for unapproved-drug actions) have ongoing programs.

FTC v. Redwood Scientific Technologies (2018)

In 2018 the FTC filed case 172-3117-X190001 against Jason Cardiff and Redwood Scientific Technologies, Inc. The complaint targeted deceptive weight-loss and smoking-cessation “strip” products that were marketed as having scientifically validated physiological effects without supporting clinical evidence. The case ended in a 2020 default judgment.^[13]

The case is a useful reference because it demonstrates the federal framework for actions against patch- and strip-format products that claim weight-loss efficacy without substantiation: false advertising under FTC Act § 5 plus, where applicable, distribution of unapproved new drugs under the Federal Food, Drug, and Cosmetic Act.

FDA fraud and warning-letter databases

Two FDA databases catalogue ongoing enforcement against products making unsubstantiated weight-loss claims, including topical patches:

FDA Tainted Weight Loss Products database — identifies dietary-supplement-style products found to contain undisclosed pharmaceutical ingredients (e.g., sibutramine, phenolphthalein) and products making fraudulent weight-loss claims.
FDA Warning Letters database — full-text searchable archive of warning letters issued to companies distributing unapproved new drugs, including unapproved weight-loss products.

The FDA’s consumer-facing guidance, Avoiding Fraudulent Weight Loss Products, summarizes the agency’s position: claims of effortless weight loss, claims of results without diet or exercise, and product formats that bypass the regulatory pathway for FDA-approved obesity drugs should be treated as red flags.^[14]

Red flags on any “GLP-1 patch” listing

Claims of semaglutide, tirzepatide, or Ozempic in a topical patch.
No FDA approval number, no NDA number, no DailyMed entry.
“Natural Ozempic” framing without disclosing the actual ingredient list.
Sold without prescription on social media, MLM sites, or unbranded e-commerce.
Mechanism described as “biofield,” “frequency,” or “energy.”

If you don’t want injections, here are the FDA-approved alternatives

The reason people search for “GLP-1 patches” is usually straightforward: they want a needle-free option. That goal is legitimate. The good news is that two FDA-approved oral GLP-1 receptor agonists exist, both available by prescription from a licensed prescriber.

Rybelsus (oral semaglutide)

Rybelsus (Novo Nordisk) is the oral-tablet form of semaglutide, FDA-approved in September 2019 for type 2 diabetes. It is not FDA-approved for weight loss — clinicians prescribe it off-label for that purpose. Absorption depends on the SNAC excipient and requires a strict fasting protocol: taken on an empty stomach, with at most 4 oz of plain water, at least 30 minutes before any food, drink, or other oral medication. Oral semaglutide bioavailability is approximately 1%, which is why the dose required for the tablet (3 / 7 / 14 mg daily) is far higher than the injectable (0.25 / 0.5 / 1 / 2 mg weekly).^[15]

Foundayo (oral orforglipron)

Foundayo (Eli Lilly) is the oral-tablet form of orforglipron, FDA-approved April 1, 2026, for chronic weight management — the first oral medication specifically FDA-approved for weight loss in the GLP-1 era. Orforglipron is a non-peptide small molecule (approximately 487 Da), which means it sidesteps the peptide delivery problem entirely. There is no absorption enhancer, no fasting protocol, and no injection. The ATTAIN-1 trial showed mean body-weight reduction of −11.1% (about −24.9 lbs) at the 17.2 mg dose over 72 weeks in adults without type 2 diabetes.^[9]^[16]

For the deeper Foundayo profile — trial population, dose ladder, side-effect profile, and how it compares to Wegovy and Zepbound — see what is orforglipron (Foundayo) and how does it work. For purchasing pathways, see where to buy Foundayo legally.

If oral isn’t enough, the injection options

For most patients, the injectable GLP-1s remain the highest-efficacy option: tirzepatide (Zepbound) at −20.9% body weight at 72 weeks^[7], semaglutide (Wegovy) at −14.9% at 68 weeks^[6], and liraglutide (Saxenda) at −8.0% at 56 weeks^[8]. The needle is a small subcutaneous pen, used once weekly (Zepbound, Wegovy, Ozempic), once daily (Saxenda), or via prefilled syringe. For an evidence-based comparison of the oral and injectable options, see our full GLP-1 medication reference.

Bottom line

No FDA-approved GLP-1 transdermal patch exists as of May 2026, and no NDA filing for one is publicly underway.
The peptides used in Wegovy, Zepbound, Saxenda, Ozempic, Mounjaro, and Victoza are 7-10x larger than the 500 Dalton upper limit for passive skin penetration. The biology rules out a passive patch.
Products sold as “GLP-1 patches” are acupressure stickers, herbal “belly fat” patches, compounded peptide creams with no realistic mechanism, or MLM “lifestyle” patches. None deliver a GLP-1 receptor agonist.
The FTC’s 2018 case against Redwood Scientific Technologies and the FDA’s Tainted Weight Loss Products and Warning Letters databases catalogue ongoing enforcement against fraudulent weight-loss patch and strip products.
The two FDA-approved needle-free options are oral tablets, not patches: Rybelsus (oral semaglutide; T2D-only, off-label for weight) and Foundayo (oral orforglipron; FDA-approved April 2026 for chronic weight management, −11.1% mean weight loss in ATTAIN-1).

Frequently asked questions

Full GLP-1 medication list reference — every FDA-approved GLP-1 with brand, manufacturer, indication, dose ladder, and DailyMed SetID links.
What is orforglipron (Foundayo) and how does it work — the first FDA-approved oral medication for chronic weight management; trial data, mechanism, and dose schedule.
Where to buy Foundayo legally — legitimate purchasing pathways for the FDA-approved oral GLP-1.
Where to buy semaglutide legally — Wegovy, Ozempic, Rybelsus, and the compounded landscape post-February 2025.
Peptides for weight loss: evidence review — the three categories of weight-loss peptides; which have Phase 3 evidence and which do not.
TikTok water, lemon, and chia weight-loss myths — companion debunker for the broader “natural Ozempic” hype cluster.
Best oral peptides for weight loss: evidence vs. hype — deeper look at why oral and non-injectable peptide delivery is so constrained.

References

1.Bos JD, Meinardi MMHM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Canonical reference establishing that only molecules with a molecular weight under approximately 500 Daltons reliably traverse the human stratum corneum, the skin's outermost barrier layer. Exp Dermatol. 2000. PMID: 10839713.
2.Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Semaglutide is a 31-amino-acid synthetic GLP-1 receptor agonist analogue with a C18 fatty-diacid side chain enabling albumin binding; molecular weight 4113.58 Daltons. J Med Chem. 2015. PMID: 26308095.
3.Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Tirzepatide is a 39-amino-acid dual GIP/GLP-1 receptor agonist peptide; molecular weight 4813.53 Daltons. Mol Metab. 2018. PMID: 30473097.
4.Drucker DJ. Advances in oral peptide therapeutics. Review of why peptide drugs are predominantly injected: poor oral bioavailability, gastric and intestinal protease degradation, and the molecular-weight barrier to membrane permeation. Discusses absorption-enhancer strategies (SNAC) and limits of non-injectable peptide delivery. Nat Rev Drug Discov. 2020. PMID: 31848464.
5.Aroda VR, Blonde L, Pratley RE. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) is the absorption enhancer that makes Rybelsus possible; absolute oral bioavailability is approximately 1% and requires strict fasting administration. Rev Endocr Metab Disord. 2022. PMID: 35838946.
6.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). Semaglutide 2.4 mg weekly produced mean body-weight reduction of -14.9% vs -2.4% placebo at 68 weeks. N Engl J Med. 2021. PMID: 33567185.
7.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). Tirzepatide 15 mg weekly produced mean body-weight reduction of -20.9% vs -3.1% placebo at 72 weeks. N Engl J Med. 2022. PMID: 35658024.
8.Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). Liraglutide 3.0 mg daily produced mean body-weight reduction of -8.0% vs -2.6% placebo at 56 weeks. N Engl J Med. 2015. PMID: 26132939.
9.Wharton S, Blüher M, Hovingh GK, Pedersen SD, Wilding JPH, Hesse D, et al.; ATTAIN-1 Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). Orforglipron 17.2 mg daily produced mean body-weight reduction of -11.1% over 72 weeks in adults with obesity and without type 2 diabetes. Orforglipron is a non-peptide small-molecule (approximately 487 Da), enabling once-daily oral dosing without an absorption enhancer. N Engl J Med. 2025. PMID: 40960239.
10.Woo CR, Lee J, Park HJ, Kim JS, Lee H, Choe S, et al. Fabrication and Preclinical Evaluation of Hyaluronic Acid/Aminoclay Nanocomposite Microneedles for Noninvasive Delivery of Semaglutide in Anti-Obesity Therapy. Preclinical formulation study (rodent model); no human Phase 1, 2, or 3 trial. Int J Nanomedicine. 2025. PMID: 41030572.
11.Singh P, Carrier A, Chen Y, Lin S, Wang H, Chen R, et al. Single-Administration Self-Boosting Microneedle Patch for The Treatment of Obesity. Proof-of-concept dissolvable microneedle array; preclinical rodent study; no FDA filing or human trial. Adv Ther (Weinh). 2024. PMID: 39429250.
12.Hua K, Hu DH, Zou Y, Ji X, Tan B, Lu W, Wei Y, Xu Y. Effects of auricular stimulation on weight- and obesity-related parameters: a systematic review and meta-analysis of randomized controlled clinical trials. Auricular acupressure / acupuncture meta-analysis showing modest effects across predominantly low-quality trials; mechanism is NOT GLP-1 receptor agonism. Front Neurosci. 2024. PMID: 39165337.
13.U.S. Federal Trade Commission. Jason Cardiff (Redwood Scientific Technologies, Inc.) — FTC case 172-3117-X190001. 2018 enforcement action against deceptive weight-loss and smoking-cessation 'strip' products. Default judgment 2020. U.S. Federal Trade Commission. 2020. https://www.ftc.gov/legal-library/browse/cases-proceedings/172-3117-x190001-jason-cardiff-redwood-scientific-technologies-inc
14.U.S. Food and Drug Administration. Avoiding Fraudulent Weight Loss Products — FDA consumer guidance on weight-loss products making unsubstantiated claims, including topical patches, creams, and over-the-counter supplements. Companion: FDA Tainted Weight Loss Products database and FDA Warning Letters database. U.S. Food and Drug Administration. 2025. https://www.fda.gov/consumers/consumer-updates/avoiding-fraudulent-weight-loss-products
15.Novo Nordisk Inc. RYBELSUS (semaglutide) tablets, for oral use — US Prescribing Information. FDA-approved September 2019 for type 2 diabetes. Not FDA-approved for weight loss. Absorption depends on the SNAC excipient and requires strict fasting administration with at most 4 oz of plain water 30 minutes before food. Semaglutide oral bioavailability is approximately 1%. FDA Approved Labeling (DailyMed NIH). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
16.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets, for oral use — US Prescribing Information. FDA-approved April 1, 2026 for chronic weight management. Orforglipron is a non-peptide small-molecule GLP-1 receptor agonist (molecular weight approximately 487 Da); once-daily oral dosing without absorption enhancer or fasting protocol. ATTAIN-1 mean body-weight reduction -11.1% at 17.2 mg over 72 weeks. FDA Approved Labeling (DailyMed NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62

Important disclaimer. This article is educational information only — not medical advice and not a substitute for consultation with a licensed prescriber. “GLP-1 patches” is a YMYL (Your Money or Your Life) topic. Every regulatory and molecular claim in this article is anchored to a primary source (DailyMed, PubMed, FDA, or FTC) and should be independently verified by your prescriber. Weight Loss Rankings does not prescribe, dispense, or endorse any specific medication, compounding pharmacy, or topical product. Product categories are described generically; no individual seller is named.